<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2019-12-4-64-69</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-338</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНО-ЛАБОРАТОРНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL AND LABORATORY STUDIES</subject></subj-group></article-categories><title-group><article-title>Изучение патогенетического значения катехоламинов в развитии ретинопатии недоношенных на экспериментальной модели заболевания</article-title><trans-title-group xml:lang="en"><trans-title>Studying the pathogenic role of catecholamines in the development of retinopathy of prematurity on an experimental model of the disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Катаргина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Katargina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заместитель директора</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062, Россия</p></bio><bio xml:lang="en"><p>Dr. of Med. Sci., Professor, deputy director</p><p>14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-офтальмолог отдела патологии глаз у детей</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062, Россия</p></bio><bio xml:lang="en"><p>researcher, department of children’s eye pathology</p><p>14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia</p></bio><email xlink:type="simple">natashamma@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Panova</surname><given-names>A. J.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант отдела патологии глаз у детей</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062, Россия</p></bio><bio xml:lang="en"><p>PhD student, department of children’s eye pathology</p><p>14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондаренко</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarenko</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник лаборатории нервных и нейроэндокринных регуляций</p><p>ул. Вавилова, д. 26, Москва, 119334, Россия</p></bio><bio xml:lang="en"><p>researcher, laboratory of nervous and neuroendocrine regulation</p><p>26, Vavilov St., Moscow, 119334, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никишина</surname><given-names>Ю. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikishina</surname><given-names>Yu. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник лаборатории нервных и нейроэндокринных регуляций</p><p>ул. Вавилова, д. 26, Москва, 119334, Россия</p></bio><bio xml:lang="en"><p>researcher, laboratory of nervous and neuroendocrine regulation</p><p>26, Vavilov St., Moscow, 119334, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муртазина</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Murtazina</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант лаборатории нервных и нейроэндокринных регуляций</p><p>ул. Вавилова, д. 26, Москва, 119334, Россия</p></bio><bio xml:lang="en"><p>junior researcher, laboratory of nervous and neuroendocrine regulation</p><p>26, Vavilov St., Moscow, 119334, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Угрюмов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ugryumov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>академик РАН, д-р биол. наук, профессор, заведующий лабораторией нервных и нейроэндокринных регуляций</p><p>ул. Вавилова, д. 26, Москва, 119334, Россия</p></bio><bio xml:lang="en"><p>Academician of the Russian Academy of Sciences, Dr. Biol. Sci., Professor, head, laboratory of nervous and neuroendocrine regulation</p><p>26, Vavilov St., Moscow, 119334, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН «Институт биологии развития им. Н.К. Кольцова» РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Koltsov Institute of Developmental Biology, Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2019</year></pub-date><volume>12</volume><issue>4</issue><fpage>64</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Катаргина Л.А., Осипова Н.А., Панова А.Ю., Бондаренко Н.С., Никишина Ю.О., Муртазина А.Р., Угрюмов М.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Катаргина Л.А., Осипова Н.А., Панова А.Ю., Бондаренко Н.С., Никишина Ю.О., Муртазина А.Р., Угрюмов М.В.</copyright-holder><copyright-holder xml:lang="en">Katargina L.A., Osipova N.A., Panova A.J., Bondarenko N.S., Nikishina Y.O., Murtazina A.R., Ugryumov M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/338">https://roj.igb.ru/jour/article/view/338</self-uri><abstract><p>Цель — изучить участие дофамина и норадреналина в патогенезе ретинопатии недоношенных (РН) на оригинальной крысиной модели заболевания.</p><sec><title>Материал и методы</title><p>Материал и методы. Экспериментальные животные — 41 новорожденный крысенок породы Вистар (82 глаза) — были разделены на 2 группы: опытную — крысята с экспериментальной РН (ЭРН) (n = 21) и контрольную (n = 20). Крысят выводили из эксперимента на 7-е, 14-е, 23-и и 28-е сутки жизни. Всем животным в указанные сроки проводили бинокулярную энуклеацию, из глазного бокала выделяли сетчатку. В супернатанте сетчатки определяли содержание норадреналина, дофамина и предшественника дофамина — L-3,4 дигидроксифенилаланина (L-ДОФА) при помощи обращенно-фазовой высокоэффективной жидкостной хроматографии с электрохимической детекцией (Amperometric detector LC-4B, Bioanalytical Systems, США) при потенциале 850 мВ.</p></sec><sec><title>Результаты</title><p>Результаты. На 7-е сутки, соотве тствующие существованию аваскулярных зон сетчатки в обеих группах животных, достоверных различий по содержанию моноаминов в сетчатке крысят с ЭРН и в контрольной группе не выявлено. На 14-е сутки содержание норадреналина, дофамина и L-ДОФА в сетчатке опытной группы было достоверно повышено по сравнению с контролем. На 23-и сутки, соответствующие пику неоваскуляризации в применяемой модели ЭРН, уровень норадреналина в сетчатке крысят опытной группы был достоверно выше, а уровень L-ДОФА достоверно ниже, чем в группе контроля; уровень дофамина был сравним в обеих группах и сопоставим с уровнем L-ДОФА в контрольной группе. На 28-е сутки, соответствующие началу регресса ЭРН со снижением сосудистой активности, содержание дофамина и L-ДОФА оставалось сниженным по сравнению с группой контроля.</p></sec><sec><title>Заключение</title><p>Заключение. В процессе развития патологической неоваскуляризации в сетчатке крысят с ЭРН нарастает уровень норадреналина с пиком, соответствующим сроку выраженного патологического роста ретинальных сосудов в применяемой модели, что свидетельствует о его проангиогенных свойствах и непосредственном участии в патогенезе РН. Уровень дофамина и L-ДОФА при развитии ЭРН к 14-м суткам повышался по сравнению с 7-ми сутками, что может быть связано с созреванием продуцирующих амакриновых клеток, а затем на 23-и сутки, т. е. на сроке, соответствующем максимальному пику ангиогенеза, отмечалось относительное снижение L-ДОФА. Можно предположить, что недостаток данного моноамина, а значит, и недостаточное проявление антиангиогенных свойств вносит вклад в развитие бесконтрольной неоваскуляризации сетчатки.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. To study the involvement of dopamine and noradrenaline in the pathogenesis of retinopathy of prematurity (ROP) on an original rat model of the disease.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study was conducted on 41 newborn Wistar rats (82 eyes), divided into 2 groups: experimental (EROP, rats with experimental ROP, n = 21) and control (n = 20). The rats were taken out of the experiment on the 7th, 14th, 23rd and 28th days of life. All rat pups were given binocular enucleation at the indicated times, whereupon the eyeballs were dissected along the limbus and the cornea, lens, hyaloid system, and vitreous were removed. The retina was isolated from the eye cup. The isolated retinal samples were homogenized in 10 volumes of 0.1 n HClO4 containing 50 pmol/ml (or more) of 3,4-dihydroxybenzylamine (DBA), using an ultrasonic homogenizer (Labsonic M, Sartorius), centrifuged at 2000g for 20 minutes, and the norepinephrine, dopamine and precursor of dopamine — L-3,4 dihydroxyphenylalanine (L-DOPA) were determined in the resulting supernatant. The contents of substances were measured using reverse phase high performance liquid chromatography with electrochemical detection (Amperometric detector LC-4B, Bioanalytical Systems, USA) set at the potential of 850 mV.</p></sec><sec><title>Results</title><p>Results. On the 7th day, on which avascular retinal zones in both groups of animals existed, no significant differences were found in the content of monoamines in the retina of rats with EROP and in the control group. On the 28th day, the content of noradrenaline, dopamine and L-DOPA in the retina of the experimental group was significantly increased compared with the control. On day 23, corresponding to the peak of neovascularization in the EROP model applied, the level of norepinephrine in the retina of experimental group rats was significantly higher, while the level of L-DOPA was significantly lower compared to the control group. The dopamine level was comparable in both study groups and similar to the level of L-DOPA in the control group. On the 28th day, corresponding to the beginning of EROP regression accompanied by vascular activity decrease, the content of dopamine and L-DOPA remained lower than in the control group.</p></sec><sec><title>Conclusion</title><p>Conclusion. During the development of pathological neovascularization of rat pup retina with EROP, the level of noradrenaline is growing, revealing a peak corresponding to the period of pronounced pathological growth of retinal vessels within the applied model, which indicates to the fact of noradrenalin proangiogenic properties and its direct participation in the pathogenesis of ROP. The level of dopamine and its predecessor, L-DOPA, increased towards the 14th day as compared to its level detected on the 7th day, which may be due to the maturation of the amacrine cells producing, and then, on the day 23. i. e. during the period corresponding to the maximum peak of angiogenesis, its relative decrease of L-DOPA was noted. It can be assumed that the lack of this monoamine, and hence insufficient manifestation of its anti-angiogenic properties contributes to the development of uncontrolled neovascularization of the retina.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ретинопатия недоношенных</kwd><kwd>эксперимент</kwd><kwd>крысиная модель</kwd><kwd>патогенез</kwd><kwd>норадреналин</kwd><kwd>дофамин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>retinopathy of prematurity</kwd><kwd>experiment</kwd><kwd>rat model</kwd><kwd>pathogenesis</kwd><kwd>norepinephrine</kwd><kwd>dopamine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chakroborty D., Sarkar C., Yu H., et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. In: Proc. of the National Academy of Sciences of the United States of America. 2011; 108 (51): 20730–5. doi:10.1073/pnas.1108696108</mixed-citation><mixed-citation xml:lang="en">Chakroborty D., Sarkar C., Yu H., et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. In: Proc. of the National Academy of Sciences of the United States of America. 2011; 108 (51): 20730–5. doi:10.1073/pnas.1108696108</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno-Smith M., Lutgendorf S.K., Sood A.K. Impact of stress on cancer metastasis. Future Oncol. 2010; 6 (12): 1863–81. doi: 10.2217/fon.10.142</mixed-citation><mixed-citation xml:lang="en">Moreno-Smith M., Lutgendorf S.K., Sood A.K. Impact of stress on cancer metastasis. Future Oncol. 2010; 6 (12): 1863–81. doi: 10.2217/fon.10.142</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dvorak H.F. Angiogenesis: update 2005. J. Thromb. Haemost. 2005; 3 (8): 1835–42. doi: 10.1111/j.1538-7836.2005.01361.x</mixed-citation><mixed-citation xml:lang="en">Dvorak H.F. Angiogenesis: update 2005. J. Thromb. Haemost. 2005; 3 (8): 1835–42. doi: 10.1111/j.1538-7836.2005.01361.x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dal Monte M., Cammalleri M., Mattei E., et al. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest. Ophthal. Vis. Sci. 2015; 56 (1): 59–73. doi:10.1167/iovs.14-15263</mixed-citation><mixed-citation xml:lang="en">Dal Monte M., Cammalleri M., Mattei E., et al. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest. Ophthal. Vis. Sci. 2015; 56 (1): 59–73. doi:10.1167/iovs.14-15263</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Makhoul I.R., Peleg O., Miller B., et al. Oral propranolol vs placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Arch. Dis. Child. 2013; 98: 565–7. doi: 10.1136/archdischild-2013-303951</mixed-citation><mixed-citation xml:lang="en">Makhoul I.R., Peleg O., Miller B., et al. Oral propranolol vs placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Arch. Dis. Child. 2013; 98: 565–7. doi: 10.1136/archdischild-2013-303951</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Keeley P.W., Reese B.E. Morphology of dopaminergic amacrine cells in the mouse retina: independence from homotypic interactions. J. Comp. Neurol. 2010; 518: 1220–31. doi: 10.1002/cne.22270</mixed-citation><mixed-citation xml:lang="en">Keeley P.W., Reese B.E. Morphology of dopaminergic amacrine cells in the mouse retina: independence from homotypic interactions. J. Comp. Neurol. 2010; 518: 1220–31. doi: 10.1002/cne.22270</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Versaux-Botteri C., Martin-Martinelli E., Nguyen-Legros J., et al. Regional specialization of the rat retina: catecholamine-containing amacrine cell characterization and distribution. J. Comp. Neurol. 1986; 243: 422–33. doi: 10.1002/cne.902430311</mixed-citation><mixed-citation xml:lang="en">Versaux-Botteri C., Martin-Martinelli E., Nguyen-Legros J., et al. Regional specialization of the rat retina: catecholamine-containing amacrine cell characterization and distribution. J. Comp. Neurol. 1986; 243: 422–33. doi: 10.1002/cne.902430311</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Катаргина Л.А., Хорошилова-Маслова И.П., Бондаренко Н.С. и др. Ангиогенные свойства катехоламинов в аспекте патогенеза ретинопатии недоношенных. Российский офтальмологический журнал. 2018; 11 (4): 49–54. https://doi.</mixed-citation><mixed-citation xml:lang="en">Катаргина Л.А., Хорошилова-Маслова И.П., Бондаренко Н.С. и др. Ангиогенные свойства катехоламинов в аспекте патогенеза ретинопатии недоношенных. Российский офтальмологический журнал. 2018; 11 (4): 49–54. https://doi.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">org/10.21516/2072-0076-2018-11-4-49-54 Katargina L.A., Khoroshilova-Maslova I.P., Bondarenko N.S., et al. Angiogenic properties of catecholamines from the viewpoint of the pathogenesis of retinopathy of prematurity. Russian ophthalmological journal. 2018; 11 (4): 49–54 (in Russian). https://doi.org/10.21516/2072-0076-2018-11-4-49-54</mixed-citation><mixed-citation xml:lang="en">org/10.21516/2072-0076-2018-11-4-49-54 Katargina L.A., Khoroshilova-Maslova I.P., Bondarenko N.S., et al. Angiogenic properties of catecholamines from the viewpoint of the pathogenesis of retinopathy of prematurity. Russian ophthalmological journal. 2018; 11 (4): 49–54 (in Russian). https://doi.org/10.21516/2072-0076-2018-11-4-49-54</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Катаргина Л.А., Хорошилова-Маслова И.П., Майбогин А.М., Панова И.Г., Осипова Н.А. Патоморфологические особенности развития экспериментальной ретинопатии недоношенных. Международный журнал прикладных и фундаментальных исследований. 2017; 3 (2): 190–4. doi: 10.17513/mjpfi.11424 Katargina L.A., Khoroshilova-Maslova I.P., Majbogin A.M., et al. Pathomorphological features of the development of experimental retinopathy of prematurity. International Journal of Applied and Basic Research. 2017; 3 (2): 190–4 (in Russian). doi: 10.17513/mjpfi.11424</mixed-citation><mixed-citation xml:lang="en">Катаргина Л.А., Хорошилова-Маслова И.П., Майбогин А.М., Панова И.Г., Осипова Н.А. Патоморфологические особенности развития экспериментальной ретинопатии недоношенных. Международный журнал прикладных и фундаментальных исследований. 2017; 3 (2): 190–4. doi: 10.17513/mjpfi.11424 Katargina L.A., Khoroshilova-Maslova I.P., Majbogin A.M., et al. Pathomorphological features of the development of experimental retinopathy of prematurity. International Journal of Applied and Basic Research. 2017; 3 (2): 190–4 (in Russian). doi: 10.17513/mjpfi.11424</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Spix N.J., Liu L.L., Zhang Z., et al. Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygeninduced retinopathy. Invest. Ophthal. Vis. Sci. 2016; 57 (7): 3047–57. doi: 10.1167/iovs.16-19346</mixed-citation><mixed-citation xml:lang="en">Spix N.J., Liu L.L., Zhang Z., et al. Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygeninduced retinopathy. Invest. Ophthal. Vis. Sci. 2016; 57 (7): 3047–57. doi: 10.1167/iovs.16-19346</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang N., Favazza T.L., Baglieri A.M., et al. The rat with oxygeninduced retinopathy is myopic with low retinal dopamine. Invest. Ophthal. Vis. Sci. 2013; 54 (13): 8275–84. doi:10.1167/iovs.13-12544</mixed-citation><mixed-citation xml:lang="en">Zhang N., Favazza T.L., Baglieri A.M., et al. The rat with oxygeninduced retinopathy is myopic with low retinal dopamine. Invest. Ophthal. Vis. Sci. 2013; 54 (13): 8275–84. doi:10.1167/iovs.13-12544</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
